Has Jodilyn Jelsema received payments from drug or device companies?

Yes. Drug and device makers reported $10,437 in general payments to Jodilyn Jelsema across 192 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jodilyn Jelsema did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jodilyn Jelsema come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jodilyn Jelsema

General Practice · Sheffield, ALNPI 1518195460

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,151 of the $10,437 with a category attached, or 78.1%. 20 manufacturers reported payments, led by Merz North America, Inc. at 58.8% of the total. Reporting peaked in 2023 at $4,154 and has fallen 82.5% since, to $728 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,437in general payments, 2019–2025

Across 192 payments — averaging $54.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merz North America, Inc.$6K
AbbVie$2K
AstraZeneca$580
Revance Therapeutics, Inc.$343
Galderma Laboratories, L.p.$230
Amgen$218
plus $958 from 14 others

What the payments were for

Travel & lodging$2,26622%
Food & beverage$8,15178%
Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merz North America, Inc.	60	$6,137
AbbVie(2 entities)	71	$1,971
AstraZeneca	11	$580
Revance Therapeutics, Inc.	7	$343
Galderma Laboratories, L.p.	8	$230
Amgen	3	$218
Amarin Pharma, Inc.	5	$175
Novo Nordisk	4	$141
Lilly USA, LLC	8	$134
Astellas Pharma US Inc	1	$115
Sanofi-aventis U.S. LLC	1	$96
Pfizer	1	$95
Johnson & Johnson	2	$43
IBSA Pharma Inc.	2	$40
Takeda Pharmaceuticals U.S.A., Inc.	2	$37
Genentech USA, Inc.	2	$30
Boehringer Ingelheim	1	$15
Daiichi Sankyo Inc.	1	$14
GSK	1	$11
Merck	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,437 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama →

Other general practice in Sheffield

Frank TombrelloBirmingham$163K
Bradley WillisMontgomery$151K
Ashley McIntyreMontgomery$123K
John BurgessBirmingham$117K
Glenn HarnettHoover$113K
Alan ColemanAthens$30K
Darrell DoucetteHuntsville$20K
Earl RogersMobile$19K
Jennifer DoobrowCullman$16K
Robert SchusterDadeville$12K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →